Abstract
Coronavirus disease 2019 (COVID-19) pneumonia presents with severe hypoxemic respiratory failure, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The primary mode of transmission appears to be droplet-borne. Respiratory support and high levels of oxygen are required in the acute treatment of these patients. High-flow therapies have been included as part of the possible management of COVID-19.1,2 One such modality is high-flow therapy, including high-velocity nasal insufflation (HVNI), high-flow nasal oxygen (HFNO), and high-flow nasal cannulation (HFNC).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
